Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...
A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...
including a generic version of Symbicort and one other undisclosed inhalation product. Symbicort is an asthma and COPD medication with over $3 billion in annual sales, presenting a major market ...